While the FDA appears to be taking a more active role in leveraging its position to influence drug prices, the majority of efforts to bring down pharmaceutical costs are taking place at the state level.
The year began with President Trump’s accusations that pharmaceutical developers were “getting away with murder,” expectations that an executive order on drug pricing was imminent, and calls from stakeholder groups for the government to use such legislation as the Bayh-Dole Act to force drug makers to bring down high prescription drug costs. However, efforts to reduce drug prices appear to have stalled at the federal level as the major focus of congressional activity turned toward healthcare reform.
While the FDA appears to be taking a more active role in leveraging its position to influence drug prices, the majority of remaining efforts to bring down pharmaceutical costs are taking place at the state level. These state legislative efforts, as BioPharma Dive points out, tend to be aimed at narrow goals—including restricting the tactics of pharmacy benefit mangers (PBMs), tracking increased drug prices, and empowering states to impose penalties on entities that flout regulation—rather than seeking comprehensive reform.
The National Academy for State Health Policy (NASHP), a non-profit, non-partisan academy of state health policymakers, reports the following successful 2017 drug pricing initiatives:
A number of other states have bills currently in committee. Those pending efforts include a California bill that would allow for greater regulation of PBMs, an Illinois bill that would require drug makers to notify purchasers of increases in drug prices 60 days prior to the increase, a New Jersey bill that would authorize the state’s attorney general to negotiate discounts for opioid antidotes on behalf of public entities, and Pennsylvania’s effort to establish a Pharmaceutical Transparency Commission to investigate the reasonability of retail drug prices.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.